Tanabe Pharma America Inc.
- Address
- 525 Washington Boulevard Suite 1100
Sponsor Overview
Specializations
Erythropoietic Protoporphyria and X-Linked Protoporphyria
Tanabe Pharma America Inc. is involved in clinical research for Erythropoietic Protoporphyria and X-Linked Protoporphyria, rare porphyria disorders marked by heightened sensitivity to sunlight and painful cutaneous symptoms.
- Sunlight-induced pain and skin symptoms
- Phototoxicity management
- Prodromal symptom control
The sponsor’s research focus includes adult and adolescent populations affected by light-triggered burning, tingling, itching, and stinging sensations.
Dermatologic Symptom Relief
Clinical activity also centers on the reduction of cutaneous discomfort associated with sun exposure, with attention to symptom onset and severity in inherited light-sensitive disease.
- Burning sensations
- Itching and stinging
- Light-triggered symptom burden
This area reflects a therapeutic interest in improving tolerance to environmental light exposure in patients with severe photosensitivity.
Rare Disease Therapeutics
The sponsor’s research landscape includes rare disease treatment development, with emphasis on disorders affecting heme metabolism and protoporphyrin accumulation.
- Inherited metabolic disorders
- Heme pathway abnormalities
- Specialty care in rare conditions
Its clinical portfolio is concentrated on medical needs not broadly addressed by standard dermatologic therapies.
Long-Term Safety and Tolerability
Research activity also covers the ongoing evaluation of long-term safety and tolerability for an oral therapy used in EPP and XLP.
- Chronic treatment use
- Oral therapy monitoring
- Extended patient follow-up
This supports continued study of sustained treatment in people living with persistent light sensitivity and recurrent symptom episodes.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| Long-term Safety and Tolerability Evaluation of Oral Dersimelagon (MT-7117) in Erythropoietic Protoporphyria and X-Linked Protoporphyria Patients |  Bulgaria Czechia France Germany Italy Norway Poland Spain Sweden The Netherlands | Not Recruiting |
| Phase 3 Randomized Double-Blind Study of MT-7117 (Dersimelagon Phosphate) in Erythropoietic Protoporphyria and X-Linked Protoporphyria Patients | Bulgaria Czechia France Italy Poland Spain The Netherlands | Not Recruiting |
Data & Insights
This sponsor works with 1 molecule, of which 1 is not being studied by other sponsors.
This sponsor has worked with 20 sites across their trial portfolio.
Therapeutic Focus
- 1.Pathological Conditions, Signs and Symptoms1 trial91 other sponsors
- 2.Skin and Connective Tissue Diseases1 trial247 other sponsors
Partnered Research Centres
20 centres- Address
- Largo Del Pozzo 71, 41124 Modena
- Address
- Via Michele Coppino 26, 12100 Sassari
- Address
- 1 Rue Jean Burguet, 33000 Bordeaux
- Address
- 1 Place Alexis Ricordeau, 44000 Nantes
- Address
- Hindenburgdamm 30, Lichterfelde, 12203 Berlin
- Address
- Mura Delle Cappuccine 14, 16128 Genoa
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Tanabe Pharma America Inc..
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.